Document is current

Article History

Received: 26 November 2025

Accepted: 3 April 2026

First Online: 11 April 2026

Declarations

:

: All participants included in this analysis had provided general written consent. For individuals for whom obtaining consent was impractical or not feasible—such as those no longer under treatment at our institution at the time of data analysis—participation was based on presumed consent, in line with the approval of the local ethics committee (Ethics Committee of Northwestern Switzerland, EKNZ; approval number 2023 − 01246). Consequently, patients consented to the use of their health-related personal information for scientific purposes. The study was performed in compliance with the ethical principles outlined in the Declaration of Helsinki and adhered to the Good Clinical Practice (GCP) standards of the International Council for Harmonisation (ICH).

: Not applicable.

: KH: Advisory board/consulting for Apellis, Astellas, Amgen, Bayer, Novartis, Roche, Allergan/AbbVie; honoraria/support for lectures or symposia from Apellis, Bayer, Biogen, Johnson & Johnson, Novartis, Roche, Sandoz, Théa Pharma, Zeiss, Allergan/AbbVie, Heidelberg Engineering; contract research/research support from Bayer, Novartis, Roche, Allergan/AbbVie, Janssen (Johnson & Johnson), ONL Therapeutics.No financial disclosures by all other authors.